Cargando…

Pathology of Senegalese breast cancers

INTRODUCTION: Breast cancer is among the most common cancers among women in most of Africa. However, features of histologically confirmed breast cancers presenting in specific regional populations is limited. Our study describes the clinic-pathologic features of invasive breast cancer diagnosed in w...

Descripción completa

Detalles Bibliográficos
Autores principales: Fitzpatrick, Megan Burke, Rendi, Mara Hester, Kiviat, Nancy Barbara, Toure, Pape, Dem, Amadou, Sow, Papa Salif, Hawes, Stephen Edward, Feng, Qinghua, Allison, Kimberly Heller
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884722/
https://www.ncbi.nlm.nih.gov/pubmed/31819783
http://dx.doi.org/10.11604/pamj.2019.34.67.17993
_version_ 1783474603344003072
author Fitzpatrick, Megan Burke
Rendi, Mara Hester
Kiviat, Nancy Barbara
Toure, Pape
Dem, Amadou
Sow, Papa Salif
Hawes, Stephen Edward
Feng, Qinghua
Allison, Kimberly Heller
author_facet Fitzpatrick, Megan Burke
Rendi, Mara Hester
Kiviat, Nancy Barbara
Toure, Pape
Dem, Amadou
Sow, Papa Salif
Hawes, Stephen Edward
Feng, Qinghua
Allison, Kimberly Heller
author_sort Fitzpatrick, Megan Burke
collection PubMed
description INTRODUCTION: Breast cancer is among the most common cancers among women in most of Africa. However, features of histologically confirmed breast cancers presenting in specific regional populations is limited. Our study describes the clinic-pathologic features of invasive breast cancer diagnosed in women undergoing biopsy for a clinically apparent mass in Senegal, West Africa. METHODS: A prospective cohort of 522 Senegalese women presenting consecutively to Dantec Hospital (University of Dakar Tumor Institute) with a breast mass were included in the study cohort. Demographic data was collected by survey and 197 (37.7%) core needle biopsy-confirmed invasive breast cancers available for review were subsequently centrally reviewed at the University of Washington in Seattle to further to characterize the pathologic features and to perform immunohistochemistry for ER/PR and HER2. RESULTS: Seventy six (76.1%) of the 522 Senegalese women presenting for biopsy of a clinically apparent breast mass were diagnosed with invasive breast cancer. The average age of a woman with invasive cancer was 46 years old, and most (83%) presented with Stage III or IV disease. The predominant histologic subtype among the 197 biopsy-confirmed cancers was invasive ductal carcinoma (98%), with few cases of invasive lobular carcinoma (2%). Cancers were classified into four clinically relevant treatment IHC groups by combined ER/PR status and HER2 status as follows: ER-/PR-, HER2- (n=92; 46.7%), ER-/PR-, HER2+ (n=20; 10.1%), ER+/PR+, HER2- (n=76; 38.6%) and ER+/PR+, HER2+ (n=9; 4.6%). Age at time of diagnosis was similar between these four subgroups although more HER2 positive cases were pre-menopausal (p=0.05). Stage of disease at presentation differed by IHC group (p=0.008), with HER2+ cancers significantly more likely to present with stage IV disease than other IHC groups, including ER-/PR-, HER2-. There were no significant differences between groups by age group, ethnicity, place of residence or birth, or parity. CONCLUSION: Our analysis of breast cancer cases in Senegal shows a distribution of clinically relevant IHC groups like that seen in the few prior studies of breast cancer in West Africa, with higher frequencies of triple negative cancers than in most United States and European populations. Mean age at presentation, delayed presentation, and genetic/regional risk factors likely influence these differences. A better understanding of the frequencies of the pathologic features of breast cancers in the West African population may help guide future genetic studies as well as appropriate clinical management of breast cancer in these populations.
format Online
Article
Text
id pubmed-6884722
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The African Field Epidemiology Network
record_format MEDLINE/PubMed
spelling pubmed-68847222019-12-09 Pathology of Senegalese breast cancers Fitzpatrick, Megan Burke Rendi, Mara Hester Kiviat, Nancy Barbara Toure, Pape Dem, Amadou Sow, Papa Salif Hawes, Stephen Edward Feng, Qinghua Allison, Kimberly Heller Pan Afr Med J Research INTRODUCTION: Breast cancer is among the most common cancers among women in most of Africa. However, features of histologically confirmed breast cancers presenting in specific regional populations is limited. Our study describes the clinic-pathologic features of invasive breast cancer diagnosed in women undergoing biopsy for a clinically apparent mass in Senegal, West Africa. METHODS: A prospective cohort of 522 Senegalese women presenting consecutively to Dantec Hospital (University of Dakar Tumor Institute) with a breast mass were included in the study cohort. Demographic data was collected by survey and 197 (37.7%) core needle biopsy-confirmed invasive breast cancers available for review were subsequently centrally reviewed at the University of Washington in Seattle to further to characterize the pathologic features and to perform immunohistochemistry for ER/PR and HER2. RESULTS: Seventy six (76.1%) of the 522 Senegalese women presenting for biopsy of a clinically apparent breast mass were diagnosed with invasive breast cancer. The average age of a woman with invasive cancer was 46 years old, and most (83%) presented with Stage III or IV disease. The predominant histologic subtype among the 197 biopsy-confirmed cancers was invasive ductal carcinoma (98%), with few cases of invasive lobular carcinoma (2%). Cancers were classified into four clinically relevant treatment IHC groups by combined ER/PR status and HER2 status as follows: ER-/PR-, HER2- (n=92; 46.7%), ER-/PR-, HER2+ (n=20; 10.1%), ER+/PR+, HER2- (n=76; 38.6%) and ER+/PR+, HER2+ (n=9; 4.6%). Age at time of diagnosis was similar between these four subgroups although more HER2 positive cases were pre-menopausal (p=0.05). Stage of disease at presentation differed by IHC group (p=0.008), with HER2+ cancers significantly more likely to present with stage IV disease than other IHC groups, including ER-/PR-, HER2-. There were no significant differences between groups by age group, ethnicity, place of residence or birth, or parity. CONCLUSION: Our analysis of breast cancer cases in Senegal shows a distribution of clinically relevant IHC groups like that seen in the few prior studies of breast cancer in West Africa, with higher frequencies of triple negative cancers than in most United States and European populations. Mean age at presentation, delayed presentation, and genetic/regional risk factors likely influence these differences. A better understanding of the frequencies of the pathologic features of breast cancers in the West African population may help guide future genetic studies as well as appropriate clinical management of breast cancer in these populations. The African Field Epidemiology Network 2019-10-02 /pmc/articles/PMC6884722/ /pubmed/31819783 http://dx.doi.org/10.11604/pamj.2019.34.67.17993 Text en © Megan Burke Fitzpatrick et al. http://creativecommons.org/licenses/by/2.0/ The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Fitzpatrick, Megan Burke
Rendi, Mara Hester
Kiviat, Nancy Barbara
Toure, Pape
Dem, Amadou
Sow, Papa Salif
Hawes, Stephen Edward
Feng, Qinghua
Allison, Kimberly Heller
Pathology of Senegalese breast cancers
title Pathology of Senegalese breast cancers
title_full Pathology of Senegalese breast cancers
title_fullStr Pathology of Senegalese breast cancers
title_full_unstemmed Pathology of Senegalese breast cancers
title_short Pathology of Senegalese breast cancers
title_sort pathology of senegalese breast cancers
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884722/
https://www.ncbi.nlm.nih.gov/pubmed/31819783
http://dx.doi.org/10.11604/pamj.2019.34.67.17993
work_keys_str_mv AT fitzpatrickmeganburke pathologyofsenegalesebreastcancers
AT rendimarahester pathologyofsenegalesebreastcancers
AT kiviatnancybarbara pathologyofsenegalesebreastcancers
AT tourepape pathologyofsenegalesebreastcancers
AT demamadou pathologyofsenegalesebreastcancers
AT sowpapasalif pathologyofsenegalesebreastcancers
AT hawesstephenedward pathologyofsenegalesebreastcancers
AT fengqinghua pathologyofsenegalesebreastcancers
AT allisonkimberlyheller pathologyofsenegalesebreastcancers